Diligence memo · auto-generated · as of July 2, 2026

Appling Enterprises, LLC

Appling Enterprises, LLC looks over-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Appling Enterprises, LLC operates in Pharmaceuticals, based in DENTON.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Appling Enterprises, LLC has raised $700K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).

Largest single filing: $700K on 2017-12-08.

Most recent recorded round closed around 2017-12-08.

Valuation (modeled)modeled

Provath models Appling Enterprises, LLC at approximately $33M (range $392K–$375M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Over-valued. Modeled value is 1.75× the median modeled value of Pre-Seed Pharmaceuticals companies in 2016–2018 (56 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Last raise 8.6 yr ago; this sector typically re-raises about every 13 months.

Only one round on record and long silent — often defunct, acquired, or gone quiet.

Comparablesmixed

Capital scale ranks ahead of 15% of Pharmaceuticals peers (1613 compared).

Modeled value ranks above 35% of those peers.

Closest niche peers: Essentia Pharma Socal, Llc, Essentia Pharma Florida, Llc, Novellus LLC, Blake Insomnia Therapeutics, Inc., Eleusis Benefit Corporation, PBC.

Peoplefiled

1 named person on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

Modeled above niche peers — valuation risk on entry.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.